Pulling Tekturna was the justification NPC needed...

Quote

Anonymous

Guest
To have mass layoffs earlier than what was planned... They need to cut costs and expenses and show a protected bottom-line to investors...

I get it... I get it... Time to move on!
 






I agree. I'm not usually a conspiracy theorist, but this scenario wouldn't surprise me in the least. NVS has known for a while that TKT would never replace DIOs revenue. So, the the solution is to overreact to a trial by pulling back on promotion and use this act as the excuse it needed to lay off up to 50-70% of the sales force. It's logical.
 






Anonymous said:
I agree. I'm not usually a conspiracy theorist, but this scenario wouldn't surprise me in the least. NVS has known for a while that TKT would never replace DIOs revenue. So, the the solution is to overreact to a trial by pulling back on promotion and use this act as the excuse it needed to lay off up to 50-70% of the sales force. It's logical.
Click to expand...

I completely agree. The action taken as a result of Altitude, is complete overkill and every doctor I have talked to in the past several days has agreed. Logic would tell you that something else is going on.
 






Anonymous said:
I completely agree. The action taken as a result of Altitude, is complete overkill and every doctor I have talked to in the past several days has agreed. Logic would tell you that something else is going on.
Click to expand...

BINGO!!! Been planned for a while! How ironic the announcement would be made the week before Christmas. Who do they think they are freaking fooling!!!!!!!!!!
 






I had a similar conversation with my manager today. They've been looking to cut for awhile, this is the excuse for the public. There is no reason to return all samples in our inventories if most or all of us weren't getting axed. The issue is with Tek/ARB and Tek/ACEI. That is a lable update to contraindications at the most. This in not unheard of and while doctors initially would be a little ticked they'd get over it, and realize that we did the right thing. Yes the Tekturna market would change, but that's what should be investigated by the people making the big $. Besides, there are a lot of doctors that believe in Tek thereapy before and ACE or ARB. I know some of you it's not efficacious but all of the head to head data on file shows it's essentially equal to Diovan dose to dose. Unless, there is something else going on with Tekturna that hasn't gotten out, this whole thing stinks of a conspiracy like another poster suggested. The docs I've spoken to aren't convinced that this really is an issue because they have patients on Valturna, or Tek/ACE for well over a year that are doing awesome, with good results beyond hypertension. How is it that it's Stage 3 and this wasn't picked up on prior. I really believe Novartis is being way to cautious. What I can't figure out is why they added Tek to ARB or ACE. They should have put Tek vs and ARB or ACE, in preventing outcomes. Anyway this company has been a major dissapointment ever since the demise of Galvus. I don't think I've been treated like a human or with an ounce of respect since then.
 






Anonymous said:
I had a similar conversation with my manager today. They've been looking to cut for awhile, this is the excuse for the public. There is no reason to return all samples in our inventories if most or all of us weren't getting axed. The issue is with Tek/ARB and Tek/ACEI. That is a lable update to contraindications at the most. This in not unheard of and while doctors initially would be a little ticked they'd get over it, and realize that we did the right thing. Yes the Tekturna market would change, but that's what should be investigated by the people making the big $. Besides, there are a lot of doctors that believe in Tek thereapy before and ACE or ARB. I know some of you it's not efficacious but all of the head to head data on file shows it's essentially equal to Diovan dose to dose. Unless, there is something else going on with Tekturna that hasn't gotten out, this whole thing stinks of a conspiracy like another poster suggested. The docs I've spoken to aren't convinced that this really is an issue because they have patients on Valturna, or Tek/ACE for well over a year that are doing awesome, with good results beyond hypertension. How is it that it's Stage 3 and this wasn't picked up on prior. I really believe Novartis is being way to cautious. What I can't figure out is why they added Tek to ARB or ACE. They should have put Tek vs and ARB or ACE, in preventing outcomes. Anyway this company has been a major dissapointment ever since the demise of Galvus. I don't think I've been treated like a human or with an ounce of respect since then.
Click to expand...

I totally agree. After performing the Valturna Death March for 2 days, it's obvious the docs aren't nearly as concerned about Altitudes' alleged failure as Novartis is with inventing a reason to shitcan us earlier.
 






Top Bottom
Back
Quote